Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 June 2004, Vol. 103, No. 11, pp. 3999-4000.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitacre, C. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Whitacre, C. C.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow


InsideBlood

IMMUNOBIOLOGY

Spotlight on CD8 T cells in MS

Multiple sclerosis (MS) involves an autoimmune response directed against central nervous system (CNS) myelin antigens. The histologic features involving both lymphocyte and macrophage infiltration into the CNS, the role of interferon gamma (IFN-{gamma}) in causing disease exacerbations, and an animal model mediated by CD4+ T-helper 1 (Th1) lymphocytes have led to the assumption that CD4+ T cells are the primary immune culprit leading the autoimmune attack against myelin in MS. The precise identification of the target myelin antigen(s) has been debated for decades. In this issue, Crawford and colleagues (page 4222) focus on the individual T-cell types mediating the antimyelin response and the potential myelin targets using a wide spectrum of epitopes.

Crawford et al identify CNS-specific CD4+ and CD8+ T cells in untreated MS patients using a novel and comprehensive approach. Proliferative responses are evaluated using 530 serial overlapping peptides spanning the entire sequence of 9 CNS autoantigens, including myelin basic protein (MBP), myelin proteolipid protein (PLP), myelin-associated oligodendrocytic basic protein (MOBP), and 6 others. Blood mononuclear cells from patients at various stages of disease (relapsing-remitting, primary progressive, secondary progressive) are assessed for proliferation by carboxyfluorescien diacetate succinimidyl ester (CFSE) staining, specificity, phenotype, and cytokine secretion. A high prevalence of myelin peptide–reactive CD4+ T cells is demonstrable in healthy subjects and all groups of MS patients, with no significant differences in specificity between groups. Myelin-reactive CD4+ T cells in MS are more differentiated than healthy subjects with significantly increased IFN-{gamma} and decreased interleukin 4 (IL-4), IL-5, and CCR5. What is surprising about the results of Crawford et al is the extent of CD8+ T-cell responses, particularly in remitting-relapsing MS (RRMS). More than 50% of the RRMS group responded to the MOBP peptides, with CD8 responses in MS characterized by increased IFN-{gamma}, IL-10, and CXCR3.

CD8 T cells are known to be present in the CNS infiltrates in MS, and Babbe et al1 reported that these T cells expand within the lesion as evidenced by oligoclonality of the T-cell receptors. The question is, what is their function in the milieu of the CNS? Evidence for 2 opposing roles has emerged. First, in the experimental autoimmune encephalomyelitis (EAE) model of MS, MBP-specific CD8 T-cell clones transferred severe neurologic signs indicative of upper motor neuron impairment to naive or severe combined immunodeficiency (scid) mice.2 A role for IFN-{gamma} was observed, arguing for a pathologic contribution of the transferred CD8+ cells. Second, evidence suggests a regulatory role for CD8+ T cells in EAE and MS. Mice genetically depleted of CD8 T cells show greater relapses, implicating the CD8 cell in maintaining a state of disease remission.3 Crawford et al showed that proliferating CD8 T cells in MS secrete both IFN-{gamma} and IL-10, suggesting a mixture of both pathologic and regulatory populations. Interestingly, this group earlier showed that glatiramer acetate (GA) therapy administered to MS patients restored levels of GA-specific CD8+ T cells to control levels.4 Thus, increasing evidence points to both a pathologic and regulatory role for the CD8 T cells in MS, with future therapies perhaps targeted toward increasing the regulatory population.

--- Caroline C. Whitacre
Ohio State University

References

  1. Babbe H, Roers A, Waisman A, et al. Clonal expansion of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192: 393-404.[Abstract/Free Full Text]

  2. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A pathogenic role for myelin-specific CD8+ T cells in a model for multiple sclerosis. J Exp Med. 2001;194: 669-676.[Abstract/Free Full Text]

  3. Koh DR, Fung-Leung WP, Ho A, Gray D, Acha-Orbea H, Mak TW. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science. 1992;256: 1210-1213.[Abstract/Free Full Text]

  4. Karankikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) Therapy induces CD8+ T cell responses in patients with multiple sclerosis. J Clin Invest. 2002;109: 641-649.[CrossRef][Medline] [Order article via Infotrieve]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay
Michael P. Crawford, Shirley X. Yan, Sterling B. Ortega, Riyaz S. Mehta, Rachel E. Hewitt, David A. Price, Peter Stastny, Daniel C. Douek, Richard A. Koup, Michael K. Racke, and Nitin J. Karandikar
Blood 2004 103: 4222-4231. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitacre, C. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Whitacre, C. C.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020